The speakers from our January panel discussion on immunogenicity answer further questions from the live event
Thermo Fisher Scientific (MA, USA) have announced the launch of a new complementary diagnostic immunoassay, the Thermo Scientific QMS Plazomicin Immunoassay, for measuring the concentration of a novel therapeutic antibiotic, plazomicin, used to treat complicated urinary tract infections.
All immunogenicity assessments present specific challenges. As a contract research organization (CRO), a major challenge we face is related to the lack of harmonization and standardization. Find out more in this editorial from a team at LGC (Cambridgeshire, UK).
Webinar available to view on demand. In this free panel discussion, our experts will provide insights into their own research with immunogenicity including the challenges they have had to overcome, key trends they have seen and their future outlook of the development of this field.
Webinar available to view on demand. Exploring the challenges a lack of industry standardization presents for CRO project managers and scientists as well as biopharma and biotech companies.
Webinar available to view on demand. This webinar will give an overview of immunogenicity assay development, explore the impact of anti-drug antibodies on bioanalysis and review relevant case studies discussing in-study cut-point and tolerance.
As part of our Spotlight on immunogenicity, we carried out a survey to gain an insight into the trends, challenges and developments associated with immunogenicity testing. We would like to thank everyone who was able to share their thoughts by taking part in the survey.
Find out more about working with immunogenicity as well as what the future may hold for the field in this interview with Joyce Slusser (KCAS).
Find out more about what is important when outsourcing, in this interview with Lee Abberley (GSK).
In this interview, Joao discusses the molecules and products he reviews and how important it is to understand how they affect efficacy and safety in patients.